BACKGROUND: Outcome of patients with relapsed acute myeloid leukemia (AML) remains unsatisfactory. Clofarabine is a nucleoside analog with activity in adult AML. Combinations with cytarabine in AML are feasible and effective. Idarubicin is another active AML drug, which has not yet been tested with clofarabine. METHODS: The authors therefore designed a phase I study of clofarabine +/- cytarabine, plus idarubicin. Patients with primary refractory or first-relapse AML were assigned to either clofarabine plus idarubicin (CI) if previously exposed to cytarabine with a response lasting <12 months, or clofarabine and idarubicin plus cytarabine (CIA) for responses > or = 12 months, or if never exposed to cytarabine. A standard "3 + 3" phase 1 design was followed to define maximum tolerated dose (MTD). Forty-four patients were treated (23 CI; 21 CIA). RESULTS: Dose-limiting toxicities were hyperbilirubinemia and hepatic transaminase elevations for CI-treated patients in addition to mucositis and diarrhea for CIA-treated patients. MTD for CI was clofarabine 22.5 mg/m(2) intravenously daily x 5 and idarubicin 10 mg/m(2) intravenously daily x 3. MTD for CIA was clofarabine 22.5 mg/m(2) intravenously x 5, idarubicin 6 mg/m(2) intravenously x 3, and cytarabine 0.75 g/m(2) intravenously x 5 days. CONCLUSIONS: A phase 2 randomized trial is in process to compare activity between treatment arms. (c) 2008 American Cancer Society.
RCT Entities:
BACKGROUND: Outcome of patients with relapsed acute myeloid leukemia (AML) remains unsatisfactory. Clofarabine is a nucleoside analog with activity in adult AML. Combinations with cytarabine in AML are feasible and effective. Idarubicin is another active AML drug, which has not yet been tested with clofarabine. METHODS: The authors therefore designed a phase I study of clofarabine +/- cytarabine, plus idarubicin. Patients with primary refractory or first-relapse AML were assigned to either clofarabine plus idarubicin (CI) if previously exposed to cytarabine with a response lasting <12 months, or clofarabine and idarubicin plus cytarabine (CIA) for responses > or = 12 months, or if never exposed to cytarabine. A standard "3 + 3" phase 1 design was followed to define maximum tolerated dose (MTD). Forty-four patients were treated (23 CI; 21 CIA). RESULTS: Dose-limiting toxicities were hyperbilirubinemia and hepatic transaminase elevations for CI-treated patients in addition to mucositis and diarrhea for CIA-treated patients. MTD for CI was clofarabine 22.5 mg/m(2) intravenously daily x 5 and idarubicin 10 mg/m(2) intravenously daily x 3. MTD for CIA was clofarabine 22.5 mg/m(2) intravenously x 5, idarubicin 6 mg/m(2) intravenously x 3, and cytarabine 0.75 g/m(2) intravenously x 5 days. CONCLUSIONS: A phase 2 randomized trial is in process to compare activity between treatment arms. (c) 2008 American Cancer Society.
Authors: William B Parker; Paula W Allan; Abdalla E A Hassan; John A Secrist; Eric J Sorscher; William R Waud Journal: Cancer Gene Ther Date: 2003-01 Impact factor: 5.987
Authors: Sima Jeha; Paul S Gaynon; Bassem I Razzouk; Janet Franklin; Richard Kadota; Violet Shen; Lori Luchtman-Jones; Michael Rytting; Lisa R Bomgaars; Susan Rheingold; Kim Ritchey; Edythe Albano; Robert J Arceci; Stewart Goldman; Timothy Griffin; Arnold Altman; Bruce Gordon; Laurel Steinherz; Steven Weitman; Peter Steinherz Journal: J Clin Oncol Date: 2006-04-20 Impact factor: 44.544
Authors: Stefan Faderl; Varsha Gandhi; Susan O'Brien; Peter Bonate; Jorge Cortes; Elihu Estey; Miloslav Beran; William Wierda; Guillermo Garcia-Manero; Alessandra Ferrajoli; Zeev Estrov; Francis J Giles; Min Du; Monica Kwari; Michael Keating; William Plunkett; Hagop Kantarjian Journal: Blood Date: 2004-10-14 Impact factor: 22.113
Authors: Hagop M Kantarjian; Varsha Gandhi; Peter Kozuch; Stefan Faderl; Francis Giles; Jorge Cortes; Susan O'Brien; Nuhad Ibrahim; Fadlo Khuri; Min Du; Mary Beth Rios; Sima Jeha; Peter McLaughlin; William Plunkett; Michael Keating Journal: J Clin Oncol Date: 2003-03-15 Impact factor: 44.544
Authors: Hagop Kantarjian; Varsha Gandhi; Jorge Cortes; Srdan Verstovsek; Min Du; Guillermo Garcia-Manero; Francis Giles; Stefan Faderl; Susan O'Brien; Sima Jeha; Jan Davis; Zeev Shaked; Adam Craig; Michael Keating; William Plunkett; Emil J Freireich Journal: Blood Date: 2003-06-05 Impact factor: 22.113
Authors: Edward Agura; Barry Cooper; Houston Holmes; Estil Vance; Robert Brian Berryman; Christopher Maisel; Sandy Li; Giovanna Saracino; Mirjana Tadic-Ovcina; Joseph Fay Journal: Oncologist Date: 2011-01-27
Authors: Amer M Zeidan; Rebecca M Ricklis; Hetty E Carraway; Hyun D Yun; Jacqueline M Greer; B Douglas Smith; Mark J Levis; Michael A McDevitt; Keith W Pratz; Margaret M Showel; Douglas E Gladstone; Steven D Gore; Judith E Karp Journal: Br J Haematol Date: 2012-05-18 Impact factor: 6.998
Authors: J Magenau; P Westervelt; S Khaled; J McGuirk; P Hari; M Eapen; P S Becker; B Parkin; T Braun; B Logan; H Wang; M Jagasia; S D Rowley; D D H Kim; T Schechter; N Frey; B Scott; T Churay; S Lieland; S Forman; S Mineishi Journal: Bone Marrow Transplant Date: 2016-07-18 Impact factor: 5.483